IP Library Granted Patent US 9,988,354
Granted Patent B2
US 9,988,354 · App. 14/773,436 · Granted Jun 5, 2018

Salt of omecamtiv mecarbil and process for preparing salt

Inventors: Sheng Cui (Lexington, MA); Henry Morrison (Moorpark, CA); Karthik Nagapudi (Simi Valley, CA); Shawn Walker (Woodland Hills, CA); Charles Bernard (Moorpark, CA); Karl Bennett Hansen (Cohasset, MA); Neil Fred Langille (Sudbury, MA); Alan Martin Allgeier (Wilmington, DE); Steven Mennen (Boston, MA); Jacqueline Woo (Sherwood Park, CA)
Assignee: AMGEN INC.
C07D213/75A61K9/2013A61K9/2018A61K9/2054A61K31/496A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,988,354
App. No.
14/773,436
Granted
Jun 5, 2018
Kind
B2
Abstract

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure:

Claims (7)

1. A dihydrochloride monohydrate salt of omecamtiv mecarbil.

2. A dihydrochloride monohydrate salt of omecamtiv mecarbil, wherein the salt is crystalline and is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.6, 14.9, 20.1, 21.4, and 26.8±0.2° 2θ using Cu Kα radiation.

3. The salt of claim 2 , wherein the X-ray powder diffraction patter further comprises peaks at about 8.4, 24.2, 26.0, and 33.3±0.2° 2θ using Cu Kα radiation.

4. The salt of claim 2 , wherein the X-ray powder diffraction patter further comprises peaks at about 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7±0.2° θ using Cu Kα radiation.

5. The salt of claim 2 , having an X-ray powder diffraction pattern substantially as shown in FIG. 2 .

6. The salt of claim 2 , having an endothermic transition at about 230° C. to about 240° C., as measured by differential scanning calorimetry.

7. The salt of claim 6 , wherein the endothermic transition is at about 235° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: AMGEN INC.
To: CYTOKINETICS, INC.
Reel/Frame 057417/0709 →
Continuity (2)
Provisional Application 61785763 · Mar 14, 2013
Related Publication 20160016906A1 · Jan 21, 2016